Bicara Therapeutics Inc (BCAX) PT Raised to $18 at Goldman Sachs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts BCAX Hot Sheet
Price: $8.74 -2.46%
Rating Summary:
14 Buy, 2 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Rating Summary:
14 Buy, 2 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Join SI Premium – FREE
Goldman Sachs analyst Richard Law raised the price target on Bicara Therapeutics Inc (NASDAQ: BCAX) to $18.00 (from $16.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Goldman Sachs Downgrades Bicara Therapeutics Inc (BCAX) to Sell, 'Competitive Pressure In High Gear'
- Sportradar Group AG (SRAD) PT Raised to $16 at StoneX
- United Therapeutics Corp. (UTHR) PT Raised to $720 at Raymond James
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
